Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Manulife Financial Corp T.MFC

Alternate Symbol(s):  T.MFC.P.Q | T.MFC.P.B | T.MFC.P.C | MNQFF | T.MFC.P.F | T.MFC.P.I | T.MFC.P.J | T.MFC.P.K | T.MFC.P.L | T.MFC.P.M | T.MFC.P.N | MNLCF | MFC | T.MFC.P.P | MNUFF

Manulife Financial Corporation is a Canada-based international financial services company. The Company operates as Manulife across its offices in Asia, Canada, and Europe, and primarily as John Hancock in the United States. It provides financial advice, insurance, and wealth and asset management solutions for individuals, institutions, and retirement plan members worldwide. Its segments include... see more

TSX:MFC - Post Discussion

Manulife Financial Corp > TD Analysis
View:
Post by SunsetGrill on May 12, 2022 4:24pm

TD Analysis

Recommendation: ACTION LIST BUY
Risk: MEDIUM
12-Month Target Price: C$34.00
Prior: C$37.00
12-Month Dividend (Est.): C$1.35
12-Month Total Return: 45.2%

Market Data (C$)
Current Price C$24.35
52-Week Range $22.75 - $28.09
Mkt Cap (f.d.) ($mm) $47,287.7
Current Dividend $1.32
Dividend Yield 5.4%
Avg. Daily Trading Vol. 13,159,070
Financial Data (C$) Fiscal Y-E December Shares O/S (f.d)(mm) 1,942.0 Float Shares (mm) 1,926.0 LICAT 140% ROE 11.8%



Event MFC reported Q1/22 core EPS of $0.77, down 5% y/y (estimate: $0.82; consensus: $0.82), reflecting lower Asian new business gains (lockdowns) and lower earnings on surplus (seed capital losses), partially offset by positive experience gains. Core ROE was 11.8% and BV/share was up 13% y/y (up 13% ex-AOCI) and down 2% q/q (up 3% ex-AOCI). Relative to our estimates, lower new business gains, seed capital losses (reported in earnings on surplus), and lower WM earnings were offset by much better P/H experience (Canada). LTC P/H experience remains favourable. Impact: NEGATIVE Asia sales (US$) were down 18% y/y and 12% higher than our estimate of $742mm reflecting lockdowns in Asia (including H.K.) and much lower sales in Japan (COLI). Asian new business gains were down 49% y/y and 32% lower than our forecast indicating the new business margins were extremely weak in Asia. Lower new business margins reflect the unfavourable product mix in China and lower sales in high margin regions. Lockdowns in Asia have a significant impact on sales because most products are agency-distributed. The reach of MFC's Asian distribution and product breadth suggests sales and new business gains should recover abruptly as lockdowns are relaxed. We did not materially change our 2023E new business gain forecast (IFRS 4-based). WM net inflows of $6.9bln were up five-fold y/y and 20% lower than forecast reflecting lower fixed income sales. Asian and U.S. retirement net flows remain healthy. WM earnings were up 6% y/y and 11% lower than expected, reflecting lower AUM (impact of rates was greater than expected). The pretax margin in WM was up 40bps y/y and 60bps lower than expected. We lowered our 2022/2023 WM earnings forecast by ~15%. TD Investment Conclusion Our positive outlook on MFC reflects: 1) greater confidence that the legacy businesses will not result in material hits to reported earnings and capital strength; 2) a strong capital ratio from the perspective of LICAT and core LICAT; 3) businesses that should support growth and an improving ROE — Asian Insurance and WAM; and 4) valuation (including the impact of IFRS 17).


Valuation On our core 2022E and 2023E EPS, Manulife is trading at 7.5x and 7.2x, respectively, compared with the five-year average (two-year forward) of 7.8x. On our core 2022E EPS, Sun Life is trading at a premium P/E multiple of 10.4x.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities